AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-17. (Cancelled)

18. (Withdrawn; Currently amended) A method of preparing the preparation of claim 29 ~~stabilizing immunoglobulin preparations~~, comprising providing an aqueous polyclonal IgG ~~immunoglobulin~~ solution ~~and~~, adding proline, ~~wherein the pH of the solution is adjusted to a~~ and adjusting the pH [[of]] to a pH from about 4.2 to about 5.4~~, and wherein the preparation does not comprise nicotinamide~~.

19. (Cancelled)

20. (Withdrawn) The method of claim 18, wherein the pH is adjusted to 4.8.

21. (Withdrawn) The method of claim 18, wherein the final concentration of the proline in the preparation is from 0.2 to 0.4 M.

22. - 28. (Cancelled).

29. (Currently amended) A stable polyclonal IgG preparation ~~The preparation of claim 15~~, wherein the preparation comprises polyclonal IgG and a stabilizer comprising proline, has a pH of about 4.2 to about 5.4, and does not comprise nicotinamide ~~is a polyclonal IgG preparation~~.

30. (Previously presented) The preparation of claim 29, wherein the concentration of IgG in the preparation is 8-12% w/v.

31. (Previously presented) The preparation of claim 30, wherein the concentration of IgG in the preparation is 10% w/v.

32. (Previously presented) The preparation of claim 29, wherein said preparation has a pH of about 4.6 to about 5.0.

33. (Previously presented) The preparation of claim 29, wherein said proline is L-proline, and the concentration of L-proline in the preparation is from 0.2 to 0.3 M.

34. (Currently amended) The preparation of claim 29, wherein the preparation is a liquid preparation that ~~and~~ has not been ~~subject to lyophilization~~ lyophilized and is not lyophilized prior to administration.

35. (Currently amended) The preparation of claim 29 ~~1, wherein the preparation is a polyclonal IgG preparation~~, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 6-15% w/v.

36. (Currently amended) The preparation of claim 35, wherein the preparation is a liquid preparation that has not been ~~subject to lyophilization~~ lyophilized and is not lyophilized prior to administration.

37. (Currently amended) The preparation of claim 29 ~~1, wherein the preparation is a polyclonal IgG preparation,~~ wherein the preparation has a pH of about 4.6 to about 5.0, the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.3 M, and wherein the concentration of IgG in the preparation is 8-12% w/v.

38. (Currently amended) The preparation of claim 37, wherein the preparation is a liquid preparation that has not been ~~subject to lyophilization~~ lyophilized and is not lyophilized prior to administration.

39. (Currently amended) The ~~immunoglobulin~~ polyclonal IgG preparation of claim ~~29-1, wherein the preparation is a polyclonal IgG preparation,~~ wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 15-20% w/v.

40. (Currently amended) The preparation of claim ~~39-38~~, wherein the preparation is a liquid preparation that has not been ~~subject to lyophilization~~ lyophilized and is not lyophilized prior to administration.

41. (Currently amended) A stable liquid polyclonal IgG preparation, wherein the preparation comprises polyclonal IgG and a stabilizer consisting essentially of proline, wherein the preparation has a pH of about 4.2 to about 5.4, and wherein the preparation is not lyophilized prior to administration ~~has not been subjected to lyophilization~~.

42. (Previously presented) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 6-15% w/v.

43. (Previously presented) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation

is from 0.2 to 0.3 M, and wherein the concentration of IgG in the preparation is 8-12% w/v.

44. (Previously presented) The stable liquid polyclonal IgG preparation of claim 41, wherein the proline is L-proline and the concentration of the L-proline in the preparation is from 0.2 to 0.4 M, and wherein the concentration of IgG in the preparation is 15-20% w/v.

45. (New) The preparation of claim 39, wherein the concentration of IgG in the preparation is 20% w/v.